Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302-Reference-Cited by-同舟云学术

Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302

Published:2018-02 Issue:2 Volume:29 Page:392-397
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cella D.,Traina S.,Li T.,Johnson K.,Ho K.F.,Molina A.,Shore N.D.

Funder

Janssen Research & Development

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/2/392/23980257/mdx759.pdf

Reference19 articles.

1. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union;Clark;Health Qual Life Outcomes,2014

2. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients;Diels;Qual Life Res,2015

3. The prognostic significance of patient-reported outcomes in cancer clinical trials;Gotay;J Clin Oncol,2008

4. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension;Calvert;JAMA,2013

5. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial;Basch;J Clin Oncol,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing assessments of quality of life in contemporary prostate cancer clinical trials;Cancer;2024-07-27

2. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED);European Urology Oncology;2024-04

3. Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer;JAMA Network Open;2023-11-17

4. Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial;Acta Oncologica;2023-04-18

5. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor;Archivos Españoles de Urología;2023